Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: A matched case–control study
-
-
[1] Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, People’s Republic of China
-
[2] Department of Critical Care Medicine, Hangzhou First People’s Hospital Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 3 (Marzo), 2022, págs. 540-545
- Idioma: inglés
- Enlaces
-
Resumen
Purpose After the wide use of linezolid (LZD), numerous reports of uncontrolled studies have suggested that LZD is associated with high rates of thrombocytopenia. We conducted this matched case–control study to identify the risk factors for LZD-induced thrombocytopenia in patients with acute myeloid leukemia (AML) during the period of myelosuppression.
Methods We retrospectively retrieved laboratory and clinical data from the medical records of 180 Chinese with AML. Among them, 60 received ≥ 72 h of therapy with LZD during myelosuppression. The remaining patients who did not receive LZD therapy were matched individually in a ratio of 1:2 according to the basic characteristics of the LZD group.
Results We found that in the LZD group, age, history of liver or kidney disease, the baseline level of bilirubin, and creatinine clearance rate (CCR) did not affect the recovery time of platelets. Patients who received LZD for more than 7 days during the period of myelosuppression had a significantly longer time of platelet recovery and platelet count increase.
Conclusion The use of LZD > 7 days during the course of myelosuppression and the low level of albumin can prolong the time required for platelet count increase and recovery. Further study is needed to assess the potential adverse effects of LZD in larger AML patient populations.
